



Getting More Bang for America's R&D Buck ITIF/Brookings—January 2017





Strategies for Success

- Expand commercialization efforts at research institutions.
- Catalyze industry-university research partnerships.
- Expand regional program for technology commercialization and entrepreneurial support.
- Encourage technology adoption by assisting small and mid-sized companies in implementing these new technologies.
- Support regional industry clusters through new opportunities for federal grants.
- Build a sustainable community of innovation and economic growth.

Policy Changes

Structural Changes

Cultural Changes



- NIH/FDA: 21st Century Cures Act new funding and policies for Patient-focused Drug Development/Novel Clinical Trial design/Fast-track medical devices.
- NSF: America Competes Act expands eligible applicant rules and expands collaboration incentives.



- NSF: New rules implemented by Program Directors; Changes to Phase IIB match restrictions for f/on funding to reflect market forces; Create "Phase Zero" concept
- SBA: SBIR Increase \$ for commercialization support/flexibility on choice of vendor; SSBCI rules on conflicts of interest
- EDA: Match requirement restrictions; Increase \$ to RICs; Beef up technical and business expertise

Structural Changes

- Shift of University TTOs from Provost to Admin
- Management of I/U partnerships
 - Who leads? ERCs and I/UCRC all University led, but would argue for independent leadership (Industry or TBED).
- Leveraging best practices/regional models
 - Identify and promote
- Regional infrastructure
 - Line-of-site for access to larger companies
 - Access to capital and business expertise

Cultural Changes

- Recognition that failure is the norm, but "Fail Fast" is not always the best option
- Defeating the culture of impatience
- Shifting balance between basic research and commercialization—the role of the Fed and Research Institutions
- Tech Transfer Offices are NOT profit centers
- Investment/Co-Investment through <u>independent</u> Partnerships
- Impact Investing

2009-2014 AUTM Results

Institution	Research Expenditures	Lic	ensing Revenue	% Return	
University of Pennsylvania	\$ 5,188,900,338	\$	159,544,782	3.1%	
Drexel University	\$ 671,868,603	\$	1,642,345	0.2%	
Temple University	\$ 732,276,792	\$	16,263,773	2.2%	
Lehigh University	\$ 262,315,840	\$	953,690	0.4%	
СНОР	\$ 883,510,067	\$	1,971,401	0.2%	Rotavax
Wistar	\$ 348,502,000	\$	101,284,000	29.1%	Wyeth
Jefferson	\$ 462,163,864	\$	9,469,856	2.0%	,
Fox Chase	\$ 164,308,137		2,695,841	1.6%	
PSU	\$ 4,818,734,000	\$	3,333,392	0.3%	
СМИ	\$ 1,772,953,951	\$	50,735,170	2.9%	
Pitt	\$ 4,429,560,000	\$	56,206,745	1.3%	
Rutgers	\$ 2,764,338,404	\$	53,518,617	1.9%	
Princeton	\$ 784,213,739	\$	522,272,000	66.6%	Alimta/Lilly
Einstein	\$ 1,002,982,031	\$	30,187,282	3.0%	rDNA
Columbia	\$ 4,498,053,617	•	1,006,988,498	22.4%	Method
NJIT	\$ 601,942,772	\$	2,556,393	0.4%	Remicade
NYU	\$ 2,557,081,600	\$	1,265,168,902	49.5%	J&J
Mt. Sinai	\$ 2,139,063,380		230,010,527	10.8%	
Totals	\$ 37,584,416,203	-	3,704,289,897	9.9%	
Less the outliers	\$ 29,396,565,247	\$	808,576,497	2.8%	
National Average	\$ 365.6B		\$ 15.3B	4.2%	9

Challenges to Research Institutions:

Barriers to the successful the transfer of intellectual property to the market are well recognized and include:

- Lack of commercialization expertise
- Insufficient or inconsistent recognition and support at universities
 for research with commercial aims
- Lack of access to funds and resources supporting translational, pre-commercialization activities

Challenges to Research Institutions External:

Barriers to the successful the transfer of intellectual property to the market are well recognized and include:

- Lack of access to enough seed-stage and early-stage venture capital, including insufficient funding to support applied research aimed at enhancing the commercial potential of IP;
- Lack of management talent, workforce talent and industry-specific talent to create local companies;
- Lack of a systematic innovation partnership between university and industry;
- Lack of a "critical mass" of supportive individuals and business in these tech areas.

Recommendations:



How does an institute encourage culture change that supports entrepreneurship and translational research as fundamental to academic mission?

Change Tech Transfer culture

- Better communication between faculty and TT
- Better working relationship with outside stakeholders
- Policies that provide real incentives to faculty/students
- Policies that match real-world expectations
- License vs. Spin-out
- Increase incentives for entrepreneurial faculty/students--No penalty for entrepreneurial activities as it relates to promotion and tenure.
- Encourage cross-department/cross-School collaboration
- Increase resources for technology commercialization—prototyping, marketing, validation, investment
- Increase resources for training entrepreneurial faculty/students
 - I-Corp and other University-specific analogues

Regional Models

University Commercialization Partnerships



- Nation's first multi-institutional, university/industry regional partnership to accelerate commercialization of emerging technologies
- Ben Franklin, the University of Pennsylvania, & Drexel University founders; Funding via PA DCED
- Includes groundbreaking common IP, NDA and SRA agreements and novel revenue return formula.
- 13 Member Institutions
 - University of Pennsylvania
 - Drexel University
 - Children's Hospital of Philadelphia
 - Fox Chase Cancer Center
 - Harrisburg Univ of Science & Tech
 - Lehigh University

- · Millersville State
- Philadelphia University
- Temple University
- Thomas Jefferson University
- University of the Sciences
- Villanova University
- Widener University

2003 – 2014

\$23.5M PA funding > \$300M leveraged 72 Licenses 49 company spinouts

>900 IP assets

300+ jobs created/retained

NTI Spin-Outs (Examples)

Optofluidics (NanoTweezers[™] for Nanoparticle Analysis)

EpoXtal (Tunable RFID)

Eqalix (3D-Printed Wound Patches)

Nelum Sciences (Superhydrophobic Surfaces)

Vascular Magnetics (nano-enabled drug-eluting stents)



- Licensed novel graphene manufacturing technology for electronics and sensors.
- Developing first roll-to-roll process for graphene
- Technology developed by Dr. Charlie Johnson at the University of Pennsylvania
- Received \$400K from NTI for critical proof-of-concept
- Received >\$1M in SBIR funding from the NSF and raised \$2.6M in 2014/2015.
- Expanded to Albany NanoTech Center in 2015
- 23 jobs created and actively hiring

University Investment Partnerships

Core elements include:

- Capital pools managed by Ben Franklin
- Partner funds co-invested, side-by-side with Ben Franklin
- Individually sized & targeted
- Integrated partner involvement to support key objectives



A \$1M startup accelerator designed to assist startup companies advancing Temple-created technologies.



A \$10M alumni-driven fund designed to assist startup companies advancing Drexel-created technologies.

Coulter Foundation Model

Endowment from Wallace Coulter Foundation to establish Centers for biomedical engineering. Drexel recipient of \$20M endowment.

Projects: Invest \$700K - \$1M/year

Selection criteria:

- Clinical context
 - Unmet clinical need
 - Cycle of care
- Stakeholder analysis
- Value Proposition/Technical Development
- Envisioned Product
- Competition
- Business Proposition
 - Market Size
 - Market Dynamics
 - Business Model
- Regulatory, Legal and IP

Process and Support:

Independent assessment board with Venture/Industry volunteers

Training via Close School with access to support network of experts;

Coulter Fellows (teams of MBA, MS/Ph.D. students)





A joint effort by PACT and Ben Franklin to bring the prestigious MIT-Venture Mentoring Service (MIT-VMS) program to the Philadelphia region.

Provides free support and guidance in a team environment to entrepreneurs to help them grow and advance their companies.

Volunteer mentors with NO financial interest or conflict-of-interest.

Started Pilot Program in June 2016 — as of December 2016: 36 Mentors — all tech sectors/all skill sets

12 Mentor Teams — all stages of companies





Structured as a virtual accelerator, **FabNet** provides a network of designers, prototypers, engineers, and small manufacturers offering companies a partnership for design, rapid prototyping, and fabrication; Matching funds; and access to specialized facilities.



Greater Philadelphia MedTech Commercialization Network

Need		Need/dynamic	Partners
Access to Specialized Resources	Information	Bioinformatics	IMS Health Penn Bioinformatics CHOP Bioinformatics IntegriChain
		Market Research Healthcare Economics	IMS Health RedTeam Associates
	Physical & Operational	Access to prototyping and fabrication.	FabNet FabNet—IT FabNetPharm
	Validation and Integration	Biomarkers; proteomics/genomics	Wistar/Drexel/Penn consortium; BluePen Biomarkers
		Resources to test new technology CLIA Validation Lab	Exponent Evogen
		Cyber/HIPAA	Drexel Cybersecurity Institute Temple Cyber Group
		Clinical Trial Network Biostatistics	Provonix
	Space	Places to develop and test new technologies	Plexus; ICE; MCTC; PA Biotech; SC, Pennovation, AmpTech

Health Care Innovation Collaborative

Description

- Regional open innovation model to address health care challenges, stimulate & attract innovation, & create a virtual test bed across major institutions.
- Created in 2015 utilizing NTI model
- Nine inaugural partners

Goal

• Accelerate commercialization & adoption of health care solutions to increase quality of care and reduce costs.

Highlights

- 18-month pilot successful with continued commitment of founding partners for additional 18-months;
 - We're still talking to each other!
- Dedicated staff within CEO Council for Growth;
- Integrated with restructured Ben Franklin process for health care investments.

Partners







🞘 Penn Medicine




COMCAST





Growing the Impact Economy in Greater Philadelphia



Impact**PHL**

Goals and objectives:

- Strengthen connections and collaborations
- Increase the number of startups who become successful
- Increase the number of regional investors
- Increase participation of established
 enterprises in impact objectives
- Position the region as a leading center of the impact economy

"Science has cured every disease known to mice."

(Dave Weiner, Wistar Institute, formerly U. Penn)